---
schema_version: "secwatch.filing_event.v1"
accession: "0001549084-23-000008"
form_type: "8-K"
ticker: "CHRN"
cik: "0001549084"
company_name: "EKSO BIONICS HOLDINGS, INC."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T12:44:48.475245+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ekso Bionics reports FY 2022 revenue up 15% to $12.9M, net loss widens to $15.1M

## Summary
- Full-year revenue $12.9M (up 15% YoY); Q4 revenue $3.6M vs $4.1M year ago.
- Net loss $15.1M ($1.16 per share) for FY2022, vs $9.8M loss ($0.80 per share) in 2021.
- Gross margin declined to 48% from 60% due to higher service, supply chain, and labor costs.
- Cash at Dec 31, 2022 was $20.5M, down from $40.4M; operations used $14.7M cash.
- Completed acquisition of Parker Hannifin's HMC business (Indego product line); FDA clearance for EksoNR in MS.

## SEC filing metadata
- accession: 0001549084-23-000008
- form_type: 8-K
- ticker: CHRN
- cik: 0001549084
- company_name: EKSO BIONICS HOLDINGS, INC.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549084/000154908423000008/0001549084-23-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549084/000154908423000008/ekso-20230328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549084-23-000008
- JSON: https://secwatch.observer/filing/0001549084-23-000008.json
- Plain text: https://secwatch.observer/filing/0001549084-23-000008.txt

## Key facts
- Earnings Releases
  EKSO BIONICS HOLDINGS, INC. reported the quarter ended December 31, 2022 results: revenue $3.6 million, net income $3.2 million, EPS $0.24 per basic and diluted share.
  - Period: the quarter ended December 31, 2022
  - Revenue: $3.6 million
  - Net income: $3.2 million
  - EPS: $0.24 per basic and diluted share
  - Result: reported results
  source text: Revenue was $3.6 million for the quarter ended December 31, 2022, compared to $4.1 million for the same period in 2021. Revenue in the fourth quarter of 2022 included approximately $3.5 million in EksoHealth revenue and approximately $0.1 million in EksoWorks revenue. The Company booked a total of 27 EksoHealth devices in the fourth quarter of 2022. Gross profit for the quarter ended December 31, 2022 was $1.7 million, compared to $2.4 million in the same period in 2021, representing a gross margin of approximately 47% in the fourth quarter of 2022, compared to a gross margin for the same period in 2021 of 59%. The decline in gross margin was primarily due to an increase in service and supply chain costs, elevated labor costs, and lower average selling prices of device sales due to sales channel mix. Sales and marketing expenses for the quarter ended December 31, 2022 were $1.9 million, compared to $2.0 million for the same period in 2021. The decrease was primarily due to lower compen
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549084/000154908423000008/0001549084-23-000008-index.htm
- Earnings Releases
  EKSO BIONICS HOLDINGS, INC. reported the year ended December 31, 2022 results: revenue $12.9 million, net income $15.1 million, EPS $1.16 per basic and diluted share.
  - Period: the year ended December 31, 2022
  - Revenue: $12.9 million
  - Net income: $15.1 million
  - EPS: $1.16 per basic and diluted share
  - Result: reported results
  source text: Revenue for the full year ended December 31, 2022 was $12.9 million, compared to $11.2 million for the same period in 2021, an increase of 15%. This increase was comprised of a $2.1 million increase in EksoHealth revenue, partially offset by a $0.4 million decrease in EksoWorks revenue. Gross profit for the full year ended December 31, 2022 was approximately $6.2 million, representing a gross margin of approximately 48%, compared to gross profit of $6.7 million for the same period in 2021, representing a gross margin of 60%. The decline in gross profit was a result of lower gross margins driven by increases in service and supply chain costs, elevated labor costs, and lower average selling prices of device sales due to sales channel mix. Sales and marketing expenses for the full year ended December 31, 2022 were $7.2 million, compared to $7.3 million for the same period in 2021, a decrease of $0.1 million primarily due to improved efficiencies. Research and development expenses for the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549084/000154908423000008/0001549084-23-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.